In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
Subscribe To Our Newsletter & Stay Updated
